Clinical Trial

Cardiogenic Shock Integrated PHenotyping for Event Reduction

Study acronym: CIPHER
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to better understand the time course of different biological mechanisms involved in acute decompensated heart failure complicated by cardiogenic shock throughout the evaluation of changes and the relationship among markers of inflammation (IL-6) and markers of increased endothelial permeability (Ang-2) or endothelial glycocalyx perturbation (Syndecan-1 and HS) and throughout a targeted metabolomic approach.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-03-24; most recent amendment 2026-04-13.
Trial Details
NCT Number NCT04323371
Lead Sponsor Niguarda Hospital
Conditions Heart Failure
Enrollment 26 participants
Start Date 2020-06-30
Primary Completion 2024-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-16